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BACKGROUND & AIMS: Categorization of colon cancers into
distinct subtypes using a combination of pathway-based bio-
markers could provide insight into stage-independent vari-
ability in outcomes. METHODS: We used a polymerase chain
reaction–based assay to detect mutations in BRAF (V600E) and
in KRAS in 2720 stage III cancer samples, collected prospec-
tively from patients participating in an adjuvant chemotherapy
trial (NCCTG N0147). Tumors deﬁcient or proﬁcient in DNA
mismatch repair (MMR) were identiﬁed based on detection of
MLH1, MSH2, and MSH6 proteins and methylation of the MLH1
promoter. Findings were validated using tumor samples from a
separate set of patients with stage III cancer (n ¼ 783). Asso-
ciation with 5-year disease-free survival was evaluated using
Cox proportional hazards models. RESULTS: Tumors were
categorized into 5 subtypes based on MMR status and detection
of BRAF or KRAS mutations which were mutually exclusive.
Three subtypes were MMR proﬁcient: those with mutations in
BRAF (6.9% of samples), mutations in KRAS (35%), or tumors
lacking either BRAF or KRAS mutations (49%). Two subtypes
were MMR deﬁcient: the sporadic type (6.8%) with BRAF mu-
tation and/or or hypermethylation of MLH1 and the familial
type (2.6%), which lacked BRAFV600E or hypermethylation of
MLH1. A higher percentage of MMR-proﬁcient tumors with
BRAFV600E were proximal (76%), high-grade (44%), N2 stage
(59%), and detected in women (59%), compared with MMR-
proﬁcient tumors without BRAFV600E or KRAS mutations
(33%, 19%, 41%, and 42%, respectively; all P < .0001). A
signiﬁcantly lower proportion of patients with MMR-proﬁcient
tumors with mutant BRAF (hazard ratio ¼ 1.43; 95% conﬁ-
dence interval: 1.11–1.85; Padjusted ¼ .0065) or mutant KRAS
(hazard ratio ¼ 1.48; 95% conﬁdence interval: 1.27–1.74;
Padjusted < .0001) survived disease-free for 5 years compared
with patients whose MMR-proﬁcient tumors lacked mutations
in either gene. Disease-free survival rates of patients with
MMR-deﬁcient sporadic or familial subtypes was similar to
those of patients with MMR-proﬁcient tumors without BRAF or
KRAS mutations. The observed differences in survival rates of
patients with different tumor subtypes were validated in an
independent cohort. CONCLUSIONS: We identiﬁed subtypes of
stage III colon cancer, based on detection of mutations in BRAF
(V600E) or KRAS, and MMR status that show differences inclinical and pathologic features and disease-free survival. Pa-
tients with MMR-proﬁcient tumors and BRAF or KRAS muta-
tions had statistically shorter survival times than patients
whose tumors lacked these mutations. The tumor subtype
found in nearly half of the study cohort (MMR-proﬁcient
without BRAFV600E or KRAS mutations) had similar outcomes to
those of patients with MMR-deﬁcient cancers.
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Genetics.
olorectal cancer (CRC) is a biologically heteroge-Cneous disease that develops via distinct pathways
involving combinations of genetic and epigenetic changes.1
Deﬁning tumor subtypes based on pathway-driven alter-
ations2 has the potential to improve prognostication and
guide targeted therapy. Two well-described pathways of
colorectal tumorigenesis include chromosomal instability
(CIN) and microsatellite instability (MSI), the latter being a
consequence of deﬁcient DNA mismatch repair (dMMR).1,3
Deﬁcient MMR can result from a germline mutation in an
MMR gene (MLH1, MSH2, MSH6, PMS2), ie, Lynch syndrome
(LS). More commonly, dMMR is sporadic and is due to
epigenetic inactivation of MLH1 that is generally associated
with hypermethylation of promoter regions of cancer-speciﬁc
genes known as the CpG island methylator phenotype (CIMP)
high.3–5 Sporadic dMMR, but not LS, tumors frequently carry
the activating somatic V600E mutation in exon 15 of the
BRAF oncogene.6 BRAF is a member of the Raf kinase family
that is a regulator of the MAP kinase/ERK signaling
pathway.7,8 BRAFV600E mutations occur downstream from
and are mutually exclusive of KRAS codon 12 and 13 muta-
tions8 that are detected in 30%–40% of CRCs.9 Both sporadic
and LS-associated cancers with dMMR display a clinical
January 2015 Molecular Subtypes and Colon Cancer Prognosis 89
CL
IN
IC
AL
ATphenotype characterized by right-sided location, high-grade
histology, and abundant tumor-inﬁltrating lymphocytes.10,11
The association of BRAF, KRAS, and MMR individually
with prognosis has been studied in colon cancers by
ourselves11–13 and others.4,9,14–19 However, development of
a classiﬁer using biomarker combinations has the potential
to identify distinct tumor subtypes with varying prognoses.
Knowledge of pathways of colorectal tumorigenesis
supports the subtyping of colon cancers using data for
dMMR/MSI, MLH1 methylation or CIMP, and mutations in
BRAFV600E and KRAS oncogenes as proposed previously.2,20
Tumor classiﬁcation with these biomarkers includes
serrated pathway subtypes in addition to subtypes reﬂect-
ing the more typical adenoma-to-carcinoma sequence.2,21
CRCs developing via a traditional adenoma–carcinoma
sequence are characterized by CIN, lack of dMMR/MSI, and
carry normal copies of BRAF and KRAS genes.1 An alternate
pathway is described where KRAS mutations develop as an
early event in proﬁcient MMR cancers.2,20 Sporadic CRCs
can also develop via a serrated neoplasia pathway, named
for the pattern of crypts in precursor polyps, that is char-
acterized by BRAFV600E mutations and CIMP-high. Cancers
arising via this pathway can have deﬁcient or proﬁcient
MMR, depending on the methylation status of the MLH1
gene.21 In contrast to sporadic dMMR cancers,21 less is
known about the prognosis of proﬁcient DNA mismatch
repair (pMMR) colon cancers that carry BRAFV600E muta-
tions arising via a serrated pathway.22 CRCs with dMMR
that carry nonmutated copies of BRAF and lack MLH1
methylation can be classiﬁed as “familial,” as they are
consistent with cancers arising in LS.6 While molecular
diversity among these pathways may result in differences in
outcome, studies examining subtype classiﬁcations are
limited to a report in all stages of CRC using the Surveil-
lance, Epidemiology, and End Results Program registry from
Washington state23 and a modest-sized cohort of women.20
In patients undergoing surgical resection of CRC with
curative intent, decision making for adjuvant chemo-
therapy is based entirely on clinical stage (TNM system),
which provides an estimate of patient prognosis.24 How-
ever, extensive intrastage variability in outcomes is
observed that cannot be accurately predicted by the TNM
staging system. Accordingly, more accurate prognostic
classiﬁers are needed to further reﬁne staging beyond
TNM that can be readily implemented into clinical care.
Such classiﬁers are ideally studied in a clinical trial cohort
of same stage patients that meet strict eligibility
requirements and receiving uniform treatment. Most
published studies of molecular markers and prognosis
evaluated 5-ﬂuorouracil (5-FU)based adjuvant therapy,
and very limited data are available from patients treated
with the current standard adjuvant regimen of 5-FU, leu-
covorin, and oxaliplatin (FOLFOX).25 This is an important
issue in that treatment-related interactions with bio-
markers may exert modifying effects that can be reﬂected
in patient survival rates.
In this report, prospectively collected stage III colon
cancers from participants in a completed adjuvant chemo-
therapy trial of FOLFOX (NCCTG N0147; Alliance)26 wereclassiﬁed into molecular subtypes using data for BRAFV600E
and KRAS oncogenes, MMR protein expression, and MLH1
methylation. We then characterized the prespeciﬁed sub-
types with respect to clinicopathologic features and disease-
free survival (DFS) rates.
Materials and Methods
Study Population
Patients with resected, stage III (any T, N1 or N2, M0)
colonic adenocarcinomas participated in a phase III random-
ized trial of mFOLFOX6 or mFOLFOX6 þ cetuximab (NCCTG
N0147).26 The current analysis includes all cancers with
prospectively determined wild-type or mutated KRAS. Data for
KRAS, BRAF, MLH1 methylation, and MMR status were avail-
able on 2720 patients. A central pathology review was per-
formed. Stratiﬁcation factors included: number of metastatic
regional lymph nodes (N1: 1–3 vs N2: 4), histologic grade
(high: poorly differentiated/undifferentiated] vs low: well/
moderately differentiated), and T stage. Proximal tumor site
included cecum, ascending, hepatic ﬂexure, and transverse
colon; distal site included splenic ﬂexure, descending and
sigmoid colon. The study was approved by the Mayo Clinic
Institutional Review Board and the North Central Cancer
Treatment Group (NCCTG; now part of Alliance for Clinical
Trials in Oncology). Each participant signed an Institutional
Review Board–approved informed consent in accordance with
current guidelines. Data quality was ensured by review by
the Alliance Statistics and Data Center. All authors had access
to the study data and reviewed and approved the ﬁnal
manuscript.
BRAF and KRAS Gene Mutations
Mutation status was determined using genomic DNA
extracted from macrodissected, formalin-ﬁxed, parafﬁn-
embedded tumor tissue that contained at least 60% tumor
cells. Testing for the c.1799T>A p.V600E BRAF mutation in
exon 15 was performed using a multiplex allele-speciﬁc, real-
time polymerase chain reaction–based assay and an automated
sequencing technique.27 Primer sequences included: wild-type
forward [NED-TGATTTTGGTCATGCTACAGT]; mutant forward
[6-Fam-CAGTGATTTTGCTCTAGCTTCAGA]; and reverse
[GTTTCTTTCTAGTAACTCAGCAGC]. KRAS mutation status in
exon 2 was analyzed in extracted DNA using the DxS mutation
test kit KR-03/04 (DxS, Manchester, UK), assessing for 7
different mutations in codons 12 and 13.28 For both genes,
mutational analysis was performed in a Clinical Laboratory
Improvement Amendments–compliant laboratory at Mayo
Clinic.
DNA Mismatch Repair Proteins
MMR protein (MLH1, MSH2, and MSH6) expression was
analyzed in formalin-ﬁxed, parafﬁn-embedded tumor sections
as described previously.12 MMR protein loss was deﬁned as
absence of nuclear staining in tumor cells but positive nuclear
staining in normal colonic epithelial cells and lymphocytes.
Expression was scored by a gastrointestinal pathologist (TCS).
Tumors were categorized as having dMMR if loss of at least one
MMR protein was detected and pMMR if all proteins were
intact.
Figure 1. (A) Stage III colon
cancers were categorized
into 5 subtypes based on
mutations in BRAF (V600E)
and KRAS (exon 2) and
MMR status. BRAFV600Eand
KRAS mutations were
mutually exclusive. (B) DFS
is shown by molecular
subtype in patients treated
in an adjuvant trial of
FOLFOX-based
chemotherapy.
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Promoter methylation of MLH1 was determined in BRAF
nonmutated tumors in an effort to distinguish sporadic from
familial dMMR patients. Tumor DNA was extracted from
formalin-ﬁxed, parafﬁn-embedded tissue and bisulﬁte modi-
ﬁed using the EZ DNA Methylation Kit (Zymo Research Corp.,
Irvine, CA). Polymerase chain reaction primers were designed
to detect differences between methylated and unmethylated
DNA for the hMLH1 promoter, as described.29 Primers for the
methylation-speciﬁc polymerase chain reaction assay included:
methylated reaction (50-FAM-AACGAATTAATAGGAAGAGCGGA
TAGCG-30; 50-CGTCCCTCCCTAAAACGACTACTACCC-30), unme-
thylated reaction (50-NED-taaaaatgaattaataggaagagtggatagtg-30;
50-AATCTCTTCATCCCTCCCTAAAACA-30); polymerase chain
reaction products from these reactions were pooled (1:1 ratio)
and diluted 1:13 using the GeneScan 400HD ROX SizeStandard (Life Technologies, Foster City, CA) and formamide.
Samples were run on an ABI 3100 Analyzer and data were
analyzed using Genotyper software (Applied Biosystems, Fos-
ter City, CA).Molecular Subtype Classiﬁcations
Tumors were categorized into 5 subtypes based on
pathway-based classiﬁcations2,20,21 using MMR status and
mutations in BRAFV600E or KRAS, which were mutually exclusive
(Figure 1). We identiﬁed 3 pMMR subtypes: mutant BRAFV600E,
mutant KRAS, or tumors lacking a mutation in either BRAFV600E
or KRAS. Two subtypes were dMMR: sporadics with mutant
BRAFV600E or hypermethylation of MLH1, or familial, which lack
BRAF mutations or hypermethylation of MLH1, and have any
KRAS status.
Table 1.Demographic and Clinicopathologic Features by Molecular Subtype
pMMR dMMR
Total
(n ¼ 2720) P valuea
Nonmutated
BRAF/KRAS
(n ¼ 1331)
Mutant KRAS
(n ¼ 945)
Mutant BRAFV600E
(n ¼ 189)
Sporadic
(n ¼ 184)
Familial
(n ¼ 71)
Age, y <.0001b
Median 57.00 59.00 63.00 66.00 46.00 58.00
Range 19.00–84.00 22.00–85.00 31.00–81.00 36.00–86.00 28.00–74.00 19.00–86.00
Ref .0006c <.0001c <.0001c <.0001c
Ref <.0001c <.0001c <.0001c
Ref .0002c <.0001c
Ref <.0001c
Age, n (%) <.0001d
<50 343 (25.8) 205 (21.7) 15 (7.9) 8 (4.3) 45 (63.4) 616 (22.6)
50 988 (74.2) 740 (78.3) 174 (92.1) 176 (95.7) 26 (36.6) 2104 (77.4)
Ref .0250d <.0001d <.0001d <.0001d
Ref <.0001d <.0001d <.0001d
Ref .1497d <.0001d
Ref <.0001d
Sex, n (%) <.0001d
Female 558 (41.9) 459 (48.6) 111 (58.7) 127 (69.0) 27 (38.0) 1282 (47.1)
Male 773 (58.1) 486 (51.4) 78 (41.3) 57 (31.0) 44 (62.0) 1438 (52.9)
Ref .0017d <.0001d <.0001d .5166d
Ref .0108d <.0001d .0863d
Ref .0387d .0029d
Ref <.0001d
Race, n (%) <.0001d
White 1121 (85.8) 790 (85.9) 181 (95.8) 166 (91.2) 65 (91.5) 2323 (87.0)
Black or
African American
86 (6.6) 89 (9.7) 3 (1.6) 12 (6.6) 2 (2.8) 192 (7.2)
Asian 84 (6.4) 35 (3.8) 4 (2.1) 4 (2.2) 2 (2.8) 129 (4.8)
Other 16 (1.2) 6 (0.7) 1 (0.5) 0 (0.0) 2 (2.8) 25 (0.9)
Ref .0016d .0021d .0548d .1897d
Ref .0015d .2244d .0504e
Ref .0452e .3055e
Ref .1069e
T stage, n (%) .0005d
T1 or T2 227 (17.1) 143 (15.1) 20 (10.6) 17 (9.2) 5 (7.0) 412 (15.2)
T3 974 (73.2) 665 (70.4) 139 (73.5) 140 (76.1) 55 (77.5) 1973 (72.6)
T4 130 (9.8) 136 (14.4) 30 (15.9) 27 (14.7) 11 (15.5) 334 (12.3)
Ref .0025d .0063d .0065d .0398d
Ref .2558d .1062d .1748d
Ref .8446d .6759d
Ref .8511d
N stage, n (%) <.0001d
1–3 782 (58.8) 578 (61.2) 77 (40.7) 112 (60.9) 42 (59.2) 1591 (58.5)
4 549 (41.2) 367 (38.8) 112 (59.3) 72 (39.1) 29 (40.8) 1129 (41.5)
Ref .2477d <.0001d .5842d .9465d
Ref <.0001d .9402d .7378d
Ref .0001d .0079d
Ref .8019d
Grade, n (%) <.0001d
High 257 (19.3) 186 (19.7) 84 (44.4) 100 (54.3) 36 (50.7) 663 (24.4)
Low 1074 (80.7) 759 (80.3) 105 (55.6) 84 (45.7) 35 (49.3) 2057 (75.6)
Ref .8244d <.0001d <.0001d <.0001d
Ref <.0001d <.0001d <.0001d
Ref .0558d .3670d
.6011d
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Table 1.Continued
pMMR dMMR
Total
(n ¼ 2720) P valuea
Nonmutated
BRAF/KRAS
(n ¼ 1331)
Mutant KRAS
(n ¼ 945)
Mutant BRAFV600E
(n ¼ 189)
Sporadic
(n ¼ 184)
Familial
(n ¼ 71)
Tumor location, n (%) <.0001d
Proximal 437 (33.2) 540 (58.1) 140 (75.7) 174 (95.1) 57 (86.4) 1348 (50.3)
Distal 880 (66.8) 389 (41.9) 45 (24.3) 9 (4.9) 9 (13.6) 1332 (49.7)
Ref <.0001d <.0001d <.0001d <.0001d
Ref <.0001d <.0001d <.0001d
Ref <.0001d .0697d
Ref .0171e
Tumor subsite
location, n (%)
<.0001d
Cecum 152 (12.0) 259 (28.9) 46 (26.1) 55 (31.8) 19 (31.1) 531 (20.7)
Ascending colon 138 (10.9) 154 (17.2) 44 (25.0) 56 (32.4) 14 (23.0) 406 (15.8)
Hepatic ﬂexure 36 (2.9) 27 (3.0) 15 (8.5) 28 (16.2) 10 (16.4) 116 (4.5)
Transverse colon 72 (5.7) 74 (8.3) 27 (15.3) 26 (15.0) 9 (14.8) 208 (8.1)
Splenic ﬂexure 50 (4.0) 41 (4.6) 6 (3.4) 1 (0.6) 2 (3.3) 100 (3.9)
Descending colon 79 (6.3) 49 (5.5) 8 (4.5) 1 (0.6) 0 (0.0) 137 (5.3)
Sigmoid colon 735 (58.2) 291 (32.5) 30 (17.0) 6 (3.5) 7 (11.5) 1069 (41.6)
Ref <.0001d <.0001d <.0001d <.0001d
Ref <.0001d <.0001d <.0001d
Ref <.0001e .3361d
Ref .1415d
aP values are unadjusted.
bP value based on Kruskal–Wallis test.
cP value based on Wilcoxon rank sum test.
dP value based on c2 test.
eP value based on Fisher’s exact test.
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To validate the prognostic utility of our subtype classiﬁer,
we examined an independent cohort of stage III colon carcinoma
patients (N¼ 783) obtained from the Sage Bionetworks (Seattle,
WA) consortium that consist of case series and a clinical trial
cohort of well-annotated colon cancer patients with extended
follow-up. Among these patients, 688 of 738 (93.2%) had
received 5-FU–based adjuvant chemotherapy and of these 473
(64%) received 5-FU/leucovorin ± irinotecan in an adjuvant
study (PETACC-3). Survival data were censored at 5 years with
median follow-up of 6.1 years; 269 DFS events were observed.
Data for KRAS and BRAFV600E mutations and MMR status,
determined by MMR protein expression or MSI, were used to
classify patient tumors into the molecular subtypes as evaluated
here. Deﬁcient MMR tumors were divided based on BRAF status
alone because data for MLH1 methylation were not available.
Statistical Methods
All biomarker data were analyzed with investigators blin-
ded to patient outcomes. For patients who were alive and
disease-free, DFS was censored at the earlier date of last dis-
ease evaluation or 5 years post randomization. Analysis of the
primary study end point of DFS, deﬁned as time from date of
randomization to ﬁrst documented disease recurrence or death
(due to all causes), whichever occurred ﬁrst, was reported
previously.26 The 2 study arms were pooled given the lack of
statistically signiﬁcant differences in DFS rates,26 and the lack
of a signiﬁcant interaction (P > .38) between treatment andany of the biomarkers (ie, KRAS, BRAF, MMR) or the 5-level
molecular subtype classiﬁcation. Kruskal–Wallis (or Wilcoxon
rank-sum) and c2 (or Fisher’s exact) tests were used to
compare continuous and categorical variables, respectively,
among the 5 subtypes. Median follow-up for surviving patients
was 4.9 years (range, 0.0–8.4 years). Kaplan-Meier methods
were used to describe the distributions of DFS.30 Univariate Cox
proportional hazard models31 were used to explore the asso-
ciations of patient characteristics and biomarkers with DFS.
Thereafter, multivariable Cox models were utilized and unless
otherwise speciﬁed, all models were adjusted for stratiﬁcation
factors selected a priori12 (provided here) and 95% conﬁdence
intervals (CIs) are provided for all hazard ratios. Two-sided
P values are reported and, in general, values <.05 were
considered statistically signiﬁcant. An effort to control for
multiple comparisons was made during the planning stage by
using well-established biomarkers whose classiﬁcation is sup-
ported by the literature.2,20 Analyses were performed using SAS
version 9.3 (SAS Institute Inc, Cary, NC) and R version 2.14.32
Data collection and statistical analyses were conducted by the
Alliance Statistics and Data Center.
Results
Tumor Subtype and Clinical and Pathologic
Characteristics
Among the 2720 cases with complete data on all tumor
markers, tumors were classiﬁed into 3 pMMR subtypes
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(n ¼ 189; 6.9%) or KRAS (n ¼ 945; 34.7%), and those
lacking a mutation in these genes (n ¼ 1331; 48.9%)
(Table 1; Figure 1A). Of note, mutations in BRAFV600E and
KRAS were mutually exclusive. The 2 dMMR subtypes
included sporadic (n ¼ 184; 6.8%) tumors with BRAFV600E
mutations and/or MLH1 hypermethylation, and familial
(n ¼ 71; 2.6%) cancers that lacked BRAFV600E mutations and
had unmethylated MLH1, which is consistent with LS
(Table 1; Figure 1A). Among pMMR subtypes, patients with
BRAFV600E mutated tumors were oldest (median age, 63
years), were most likely to be women (58.7%), and had the
highest rates of proximal site (75.7%), T4 stage (15.9%),
high-grade histology (44.4%), and N2 stage (59.3%)
(Table 1). MMR-proﬁcient tumors of the mutant KRAS sub-
type were more commonly located in the proximal colon
(58.1% vs 33.2%) compared with tumors lacking mutations
in BRAFV600E or KRAS (Table 1). Within the most prevalent
subtype of pMMR tumors lacking mutations in either
BRAFV600E or KRAS, there were more men than women
compared with the other subtypes (P  .002), except for
familial dMMR patients, and 66.8% of tumors were located
in the distal colon (Table 1). Patients with sporadic dMMR
tumors had the oldest median age (66 years) at randomi-
zation among all subytpes, were most likely from women
(69.0%), had highest rate of high-grade histology (54.3%),
and nearly all (95.1%) were located in the proximal colon
(Table 1). The familial subtype of dMMR tumors was asso-
ciated with younger age, male sex, high-grade histology, and
proximal site, which are features of LS-associated colon
cancers33 (Table 1). Among colon cancers with loss of MLH1
protein expression, 80% had BRAFV600E mutations and the
remaining cases had nonmutated BRAF with promoter
hypermethylation of MLH1.
The distributions of the 5 subtypes in relation to tumor
subsite location (ie, cecum, ascending colon hepatic ﬂexure,Table 2.Five-Year Disease-Free Survival Rates by Molecular S
pMMR
Nonmutant
BRAF/KRAS Mutant KRAS Mu
All patients
Events/n 347/1331 333/945 8
5-Year rate, % (95% CI) 70.7 (68.0–73.3) 61.0 (57.6–64.4) 5
Proximal tumor
Events/n 138/437 198/540 6
5-Year rate, % (95% CI) 65.0 (60.1–69.8) 59.2 (54.7–63.7) 5
Distal tumor
Events/n 204/880 132/389 1
5-Year rate, % (95% CI) 73.7 (70.5–76.9) 62.8 (57.6–68.0) 6
N1 tumor
Events/n 143/782 162/578 2
5-Year rate, % (95% CI) 79.4 (76.3–82.5) 67.9 (63.7–72.2) 6
N2 tumor
Events/n 204/549 171/367 5
5-Year rate, % (95% CI) 58.2 (53.7–62.8) 50.1 (44.7–55.5) 4
aUnadjusted Cox model.transverse colon, splenic ﬂexure, descending colon, and
sigmoid colon) were examined (Table 1). A majority of
pMMR tumors with BRAFV600E mutations were located in
the proximal colon (75.7%), with approximately half
(51.1%) found in the cecum plus ascending colon. Nearly
half (46.1%) of cancers of the mutated KRAS subtype were
located in the cecum plus ascending colon; one third
(32.5%) were located in the sigmoid colon. Proﬁcient MMR
tumors lacking BRAFV600E or KRAS mutations were
frequently located in the sigmoid colon (58.2%), which is
typical of the CIN pathway.1 Sporadic or familial dMMR
subtypes showed a predilection for the proximal colon that
also included higher rates of hepatic ﬂexure and transverse
colon location compared with pMMR cancers.
Tumor subtype was examined in relationship to patient
race (ie, white, African American, or Asian). Compared to the
other tumor subtypes, African Americans had the highest
representation among the mutated KRAS and pMMR sub-
type (Table 1). Asian patients were most likely to have
pMMR tumors lacking mutations in BRAFV600E or KRAS and
in contrast to African Americans or whites, were more
frequently represented among familial vs sporadic dMMR
tumors.Tumor Subtype and Disease-Free Survival
Distributions of DFS rates are shown in Kaplan-Meier
curves across the 5 tumor subtypes (Figure 1B) and
5-year DFS rates are provided (Table 2). The 5-year DFS
rates for the 3 pMMR subtypes range from 55.5% (95%
CI: 48.0%62.9%) for BRAFV600E mutant, 61% (95% CI:
57.6%64.4%) for KRAS mutant, and 70.7% (95% CI:
68.0%73.3%) for tumors lacking mutations in either
gene (Table 2). DFS was not statistically different for
pMMR tumors with mutations in BRAFV600E or in KRAS
(Punadjusted ¼ .1486). Compared with the poorer outcome ofubtype
dMMR
P valueatant BRAFV600E Sporadic Familial
<.0001
0/189 56/184 17/71
5.5 (48.0–62.9) 67.3 (60.1–74.5) 72.3 (60.6–84.1)
.0005
7/140 53/174 11/57
0.9 (42.4–59.4) 67.3 (59.9–74.7) 77.6 (65.2–90.0)
.0012
3/45 3/9 4/9
6.0 (49.9–82.0) 66.7 (35.9–97.5) 38.9 (0.0–79.3)
<.0001
3/77 21/112 7/42
8.2 (57.2–79.1) 79.3 (71.3–87.4) 82.4 (70.4–94.3)
.0012
7/112 35/72 10/29
6.5 (36.6–56.5) 48.4 (36.3–60.5) 57.5 (35.9–79.1)
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ATthe BRAFV600E and KRAS mutant subtypes, favorable DFS
was observed for pMMR tumors lacking mutations in
either gene (vs mutant BRAFV600E: hazard ratio [HR] ¼
0.56; 95% CI: 0.44–0.72; vs mutant KRAS: HR ¼ 0.67; 95%
CI: 0.58–0.78; Punadjusted < .0001 for both). In addition, DFS
for the pMMR subtype without BRAFV600E or KRAS muta-
tions did not differ signiﬁcantly from the sporadic
(Punadjusted ¼ .1448) or familial (Punadjusted ¼ .8511) dMMR
subtypes (Table 3). Five-year DFS rates for sporadic and
familial dMMR subtypes were 67.3% (95% CI: 60.1%
74.5%) and 72.3% (95% CI: 60.6%84.1%), respectively,
and were not statistically different (Tables 2 and 3).
Overall, the univariate results were maintained in a
multivariable analysis after adjustment for multiple cova-
riates (Table 3).
An earlier study in this clinical trial cohort found that
tumor site and N stage signiﬁcantly altered the relationship
between MMR status and DFS.12 Accordingly, we evaluated
the prognostic impact of the 5 subtypes stratiﬁed by tumor
site and N stage. Although the interaction tests did not
achieve statistical signiﬁcance likely due to limited power
(tumor site: Padjusted ¼ .1368; N stage: Padjusted ¼ .1103), we
found that results in the overall cohort were maintained in
proximal cancers indicated by lack of signiﬁcant differences
in DFS. Among proximal tumors, 5-year DFS rates for pa-
tients with pMMR tumors lacking mutations in BRAFV600E
and KRAS or for both dMMR subtypes were signiﬁcantly
better than rates for BRAFV600E mutated or KRAS mutated
pMMR subtypes (Tables 2 and 4). Patients with proximal
dMMR tumors of the familial subtype had the highest 5-year
DFS rate (77.6%; Table 2) that did not differ signiﬁcantly
from dMMR tumors of the sporadic subtype or pMMR
tumors lacking BRAFV600E and KRAS mutations (Table 4). Of
note, DFS for dMMR tumors of the familial subtype was
poorer among distal vs proximal tumors (Table 2; Figure 2A
and B). Among distal pMMR cancers, statistically signiﬁcant
differences in DFS were found only for KRAS-mutated
tumors (vs those without KRAS and BRAF mutations), yet
statistical power was limited (Table 4). A trend toward
better DFS was found in distal vs proximal tumors withTable 3.Associations Between Molecular Subtypes and Diseas
Pair-wise comparisons HR (95
pMMR: Mut KRAS vs nonmutated KRAS/BRAF 1.488 (1.2
pMMR: Mut BRAFV600E vs nonmutated KRAS/BRAF 1.782 (1.3
pMMR: Sporadic dMMR vs nonmutated KRAS/BRAF 1.234 (0.9
Familial dMMR vs pMMR, nonmutated KRAS/BRAF 0.954 (0.5
pMMR: Mut BRAFV600E vs Mut KRAS 1.197 (0.9
Sporadic dMMR vs pMMR, Mut KRAS 0.829 (0.6
Familial dMMR vs pMMR, Mut KRAS 0.641 (0.3
Sporadic dMMR vs pMMR, Mut BRAFV600E 0.692 (0.4
Familial dMMR vs pMMR, mut BRAFV600E 0.536 (0.3
Familial dMMR vs sporadic dMMR 0.774 (0.4
Mut, mutant.
aAdjusted for age, sex, T and N stage, grade, number of lymphBRAFV600E mutations and tumors without BRAFV600E or
KRAS mutations (Table 2).
Among patients with N1 tumors, the association of tumor
subtypes with DFS did not differ signiﬁcantly from the
overall cohort (Table 2 and Figures 1B and 2C). Among pa-
tients with N2 tumors, however, poor DFS was observed for
dMMR tumors of the sporadic subtype (Table 2, Figure 2D)
that did not differ signiﬁcantly from DFS of pMMR subtypes
with mutated KRAS (Padjusted ¼ .9195) or mutated BRAFV600E
(Padjusted ¼ .8231) (Table 4). In contrast, N1 tumors of the
dMMR sporadic subtype had DFS rates that were signiﬁ-
cantly improved compared with DFS of patients with pMMR
mutated KRAS tumors (HR ¼ 0.51; 95% CI: 0.31–0.82;
Padjusted ¼ .0054), or showed a strong trend vs the mutated
BRAFV600E (HR ¼ 0.50; 95% CI: 0.28–0.91; Padjusted ¼ .0238)
subtype (Table 4 and Figure 2C).
External Validation Cohort
We attempted to validate the prognostic utility of our
classiﬁer in an independent cohort of stage III colon cancer
patients treated with 5-FU–based adjuvant chemotherapy.
Patients from this external cohort were categorized into the
same molecular subtypes as in our dataset, with the
exception that dMMR tumors were divided based on BRAF
status alone (see Materials and Methods). In this indepen-
dent cohort, a statistically signiﬁcant difference was seen
among the 5 molecular subtypes (P ¼ .014) as was
demonstrated in the primary N0147 cohort (Figure 3). A
similarly favorable outcome for pMMR tumors lacking
BRAFV600E or KRAS mutations and dMMR tumors was
observed. In addition, poorer DFS among patients with
BRAFV600E mutant or KRAS mutant pMMR cancers was
observed as reﬂected in their 5-year DFS rates (Figure 3,
Table 2). Accordingly, the key prognostic ﬁndings of our
biomarker classiﬁer were validated.
Discussion
In patients undergoing surgical resection of CRC, prog-
nosis and management are based entirely on the TNMe-Free Survival
Univariate Multivariatea
% CI) P value HR (95% CI) P value
81–1.730) <.0001 1.483 (1.267–1.736) <.0001
97–2.272) <.0001 1.430 (1.105–1.849) .0065
30–1.636) .1448 1.090 (0.801–1.482) .5850
87–1.553) .8511 0.770 (0.452–1.309) .3339
38–1.528) .1486 0.964 (0.748–1.242) .7763
24–1.100) .1938 0.735 (0.545–0.991) .0432
94–1.044) .0739 0.519 (0.306–0.881) .0151
92–0.974) .0349 0.762 (0.539–1.077) .1240
17–0.904) .0194 0.538 (0.306–0.946) .0312
50–1.331) .3541 0.706 (0.394–1.267) .2435
nodes examined, tumor location, treatment.
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ATstaging system,24 despite considerable stage-independent
variability in outcomes. Accordingly, prognostic classiﬁers
that can be readily implemented into clinical practice are
needed to enhance clinical decision making. In stage III
colon cancers from a recent adjuvant chemotherapy trial,26
we classiﬁed tumors into 5 prespeciﬁed subtypes using a
biomarker combination of BRAFV600E and KRAS mutations,
MLH1 methylation, and MMR status. On the basis of this
classiﬁcation adapted from Jass,2 we found statistically sig-
niﬁcant differences in clinicopathologic features and patient
survival rates. Importantly, no interactions were found
between biomarkers and treatment arms or between sub-
types and DFS by treatment arm that permitted pooling of
data for the study arms. Proﬁcient MMR tumors that were
nonmutated for BRAFV600E and KRAS were the most preva-
lent subtype and represented 49% of our study cohort. Two
thirds of these tumors were located in the distal colon. This
patient subtype had DFS rates that were signiﬁcantly better
than the other pMMR subtypes with mutated BRAFV600E
or KRAS, which both showed relatively poor survival rates.
In addition, the prognosis of pMMR tumors that were
nonmutated for BRAFV600E and KRAS did not differ signiﬁ-
cantly from dMMR tumors of the sporadic or familial
subtypes. When these tumors and the dMMR subtypes are
considered together, 58% of our study patients had favor-
able survival.
We identiﬁed phenotypic features of the poorly char-
acterized, pMMR subtype with BRAFV600E mutations whose
frequency was found to be similar to the dMMR sporadic
subtype. Compared with other pMMR subtypes, patients
with mutant BRAFV600E tumors were older, more likely to
be women, and had higher rates of high-grade histology
and N2 stage. Patients with pMMR mutant, BRAFV600E tu-
mors had a poor prognosis that did not differ signiﬁcantly
from that of the mutant KRAS subtype that lacked
BRAFV600E mutations given their mutual exclusivity.8
Importantly, the mutant BRAFV600E pathway leads to both
pMMR and dMMR cancers,21,34 with MLH1 hyper-
methylation being the key event that confers dMMR which
is associated with favorable prognosis.35 Both mutant
BRAFV600E pMMR and dMMR subtypes were strongly
associated with proximal tumor site (76% and 95%,
respectively). In contrast to CRCs with CIN that develop
from typical colorectal adenomas.1 BRAFV600E mutant and/
or MLH1 hypermethylated colon cancers are believed to
develop from a precursor lesion known as the sessile
serrated adenoma/polyp based on clinical and gene
expression data.21,36,37 Sessile serrated adenoma/polyps
are found predominantly in the proximal colon, carry
frequent BRAFV600E mutations, and are CIMP-high.21
BRAFV600E is an early driver mutation that promotes tu-
mor progression through methylation-induced p16/Ink4a
inactivation.38,39 Gene expression proﬁling of mutant
BRAFV600E pMMR cancers reveals up-regulation of genes
regulating epithelial mesenchymal transition and matrix
remodeling that can facilitate tumor invasion and metas-
tasis and, thereby, contribute to their poor outcome.37
Results in the overall cohort were maintained in prox-
imal cancers as indicated by a lack of signiﬁcant differences
Figure 2. DFS by molecular subtypes among (A) proximal or (B) distal stage III colon cancers. DFS by molecular subtypes
among patients with stage III colon cancer and (C) 1–3 metastatic regional lymph nodes (N1) or (D) 4 or more metastatic
regional lymph nodes (N2).
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ATin DFS. The observed DFS differences among distal tumors
are of interest, yet statistical power was limited. We also
examined the prognostic impact of our subtype classiﬁca-
tion by N stage. Within N1 cancers, we observed favorable
5-year DFS rates for pMMR tumors lacking BRAFV600E or
KRAS mutations that did not differ signiﬁcantly from both
dMMR subtypes. These data raise the question of whether
the survival of these 2 subtypes of stage III N1 patients
treated with FOLFOX might be similar to a stage II
population. In a review of data for stage II colon can-
cers from adjuvant chemotherapy trials that evaluated
FOLFOX,25,40–42 reported DFS rates are similar to those
observed in our stage III N1 tumors without BRAFV600E or
KRAS mutations or in the dMMR subtypes. This ﬁnding
suggests that N1 pMMR tumors without BRAFV600E or KRAS
mutations may have an intrinsically better prognosis irre-
spective of therapy, or alternatively, may receive greater
beneﬁt from FOLFOX vs the other subtypes. The situation in
dMMR tumors is more complex given data suggesting lack of
5-FU beneﬁt43 and the unknown beneﬁt, if any, of oxali-
platin combined with 5-FU/leucovorin in stage III dMMRpatients.19 Although the prognostic impact of molecular
subtypes in N1 cancers was similar to the overall cohort, we
unexpectedly observed poor DFS for N2 dMMR sporadic
tumors, which was not signiﬁcantly different from the poor
prognosis of N2 pMMR tumors with mutant BRAFV600E or
mutant KRAS. However, this ﬁnding was not observed
among N2 dMMR tumors of the familial subtype that
maintained their favorable HRs, and an explanation awaits
further research.
The mutant KRAS pMMR subtype had the highest per-
centage of African Americans compared with the other
subtypes, consistent with data indicating higher rates of
KRAS mutations in CRCs from African Americans.44,45
Conﬂicting data have been reported for the frequency of
dMMR/MSI in CRCs from African Americans compared with
whites,45 yet our study does not demonstrate a difference in
the rate of African Americans by MMR status. Our data for
mutant KRAS, albeit preliminary due to small patient
numbers of non-white race, suggest that colon cancers from
African Americans may be associated with this poor prog-
nostic subtype.
Figure 3. Independent
cohort of stage III colon
cancer patients used for
external validation of the
subtype classiﬁer. DFS is
shown for the individual
subtypes.
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ability of subtype classiﬁcations to predict clinical outcomes.
Recently, a CRC subtype classiﬁcation20 was applied to
tumor tissues from the Iowa Women’s Health Study, which
found differences in age at diagnosis, tumor site, and his-
tologic grade across 3 CRC subtypes deﬁned by combina-
tions of MSI, CIMP, BRAF, and KRAS status. However, no
statistically signiﬁcant differences in survival were found
across the tumor subtypes in this smaller cohort that was
limited to women.20 In contrast to our study, the authors
deﬁned a mutant BRAFV600E serrated subtype without
regard to MSI status and did not distinguish the MSI-high
familial subtype as a distinct group.20 Data shown here
and elsewhere21,37 suggest that the serrated neoplasia
pathway can give rise to colon cancer subtypes with
divergent prognoses. Our subtype classiﬁcation was more
informative than analysis of individual biomarkers.12
Among the biomarkers analyzed, dMMR status is the most
extensively studied and has been associated with favorable
survival in untreated patients and in those receiving
5-FU–based adjuvant therapy.11,12,14,17,35 The prognostic
impact of oncogenic KRAS in stage II and III colon cancers
has been inconsistent,9,12,14,17,46–48 and BRAFV600E muta-
tions have generally been associated with adverse out-
comes, particularly in metastatic CRCs.12,14,15,18,47,49,50
Importantly, we were able to validate the key ﬁndings for
the prognostic impact of our subtype classiﬁer in an inde-
pendent cohort of stage III colon cancer patients treated
with 5-FU–based adjuvant chemotherapy. This ﬁnding
supports the robustness of our classiﬁer to detect clinically
signiﬁcant prognostic differences.
Patients in our study cohort were treated with the
current standard adjuvant FOLFOX regimen, and onlylimited data are available for the prognostic impact of the
biomarkers studied here in FOLFOX-treated patients.12,19
Important strengths of our study include the large size of
our clinical trial cohort with uniform treatment, meticulous
follow-up data, and an external validation cohort. Our sub-
type classiﬁer capitalizes on common testing for KRAS and
BRAF status in clinical practice and the recommendation for
universal MMR/MSI testing by the National Comprehensive
Cancer Network. Limitations include the retrospective
design and inability to examine the predictive potential of
our subtype classiﬁer with respect to treatment response.
Although an effort was made to control for multiple
comparisons during the study planning stage by utilizing
well-established biomarkers whose classiﬁcation was sup-
ported by the literature, pairwise comparisons with P values
that are close to the .05 signiﬁcance level should be inter-
preted with caution and their clinical signiﬁcance consid-
ered. We acknowledge that other molecular events within
the subtypes may indeed impact prognosis or chemo-
sensitivity, which can contribute to the observed subtype-
speciﬁc survival differences. A potential confounder is the
use of aspirin or other nonsteroidal anti-inﬂammatory drugs
and using questionnaire data that were available from a
subset of the study population (n ¼ 1757), no evidence
was found to indicate that use of these drugs modiﬁed the
association between subtypes and DFS.
In conclusion, we found that a biomarker-based classi-
ﬁer can identify prognostically distinct subtypes within
stage III colon cancer patients that was externally validated.
We identiﬁed a phenotype associated with BRAFV600E
mutations and pMMR that was clinically aggressive as was
the mutant KRAS subtype. The pMMR subtype without BRAF
or KRAS mutations accounted for nearly half of our study
98 Sinicrope et al Gastroenterology Vol. 148, No. 1
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ATcohort and had a favorable prognosis that did not differ
signiﬁcantly from dMMR cancers. The ﬁnding that pMMR
and dMMR subtypes with BRAFV600E mutations share
certain clinical and pathologic characteristics, but have
divergent prognoses underscores the importance of testing
for MMR/MSI to distinguish them. The poor prognosis,
pMMR subtype with mutated BRAFV600E can potentially be
targeted if BRAF inhibitors can be rendered efﬁcacious in
CRCs by blocking rebound epidermal growth factor receptor
activation.51,52 Taken together, our biomarker classiﬁer
provides important prognostic information in stage III colon
cancers with implications for patient management.References
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